profit from every ₹100 of sales.
₹0₹100
Sai Life Sciences
₹1,927.60+1.18% today
+119.9% in 1 year
1-year low ₹795.001-year high ₹1,927.60
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹117.38 for every ₹1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Sai Life Sciences sold, what it kept, and what it did with the cash.
Sales went from ₹12.0 billion in 2023 to ₹21.9 billion in 2026, with ₹3.49 billion of profit last year.
SalesProfit
Sai Life Sciences vs. similar companies
Sai Life Sciences grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Sai Life Sciences | 117.4× · Very expensive | ||
 Thermo Fisher Scientific | 38.7× · Expensive | ||
 Danaher | 45.4× · Expensive | ||
 Waters | 140.8× · Very expensive | ||
 WuXi AppTec | 25.8× · Fair price |
AI analysis
An AI analyst reads Sai Life Sciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 11,969 | 14,565 | 16,946 | 21,925 | |
| 3,182 | 4,878 | 6,797 | 9,385 | |
| 768 | 1,812 | 2,671 | 4,643 | |
| 1,929 | 3,146 | 4,424 | 6,723 | |
| 100 | 828 | 1,701 | 3,489 | |
| 0.48 | 3.98 | 8.61 | 16.43 | |
| 26.6% | 33.5% | 40.1% | 42.8% | |
| 6.4% | 12.4% | 15.8% | 21.2% | |
| 0.8% | 5.7% | 10.0% | 15.9% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 21,866 | 22,751 | 31,600 | 36,261 |
| Cash | 699 | 237 | 911 | 819 |
| Total debt | 9,324 | 9,277 | 3,524 | 2,885 |
| Total liabilities | 12,986 | 13,000 | 10,316 | 11,425 |
| 8,881 | 9,751 | 21,284 | 24,837 | |
| 208 | 208 | 198 | 212 | |
| 3.9% | 7.7% | 9.2% | 13.7% | |
| 1.1% | 8.5% | 8.0% | 14.0% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 2,194 | 2,631 | 3,140 | 5,091 | |
| 1,131 | 1,817 | 3,693 | 5,930 | |
| 1,063 | 814 | -552 | -838 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 8 | 23 | 25 | 21 |
Valuation
- 117.4×
- –
- 0.52
- 15.3×
- 18.7×
- –
- 61.2×
- -0.2%
- 0.9%
- –
Profitability
- 42.8%
- 21.2%
- 15.9%
- –
- 13.7%
- 8.6%
- –
- –
- –
- –
Growth
- +22.4%
- +224.6%
- –
- –
- +0.7%
Financial health
- 0.3×
- 0.12
- –
- 12.9×
- 1.69
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 17%of 963
Top 22%of 894
Bottom 6%of 632
Top 24%of 908
Bottom 35%of 991
News
Nvidia Stock Falls. It Faces One Big Threat in Life After Jensen.Yahoo Finance · Nov 13, 2026In 1957, A Pediatrician Signed Up For An Investing Class In Omaha. She Decided To Invest Half Her Life Savings With The Teacher. His Name Was Warren Buffett. At 71 Years Old She Was Still Practicing Medicine And Carol Angle’s Family Fortune Was $300 Million.Yahoo Finance · Nov 11, 2026Funeral homes are finding new life hosting weddings and golf outings, as the traditional burial business dies outMarketWatch · Nov 9, 2026‘My life could be cut short’: I’m 55, married and have a brain tumor. Should I splash out on a $210,000 Porsche?MarketWatch · Nov 9, 2026AI in Life Sciences Market to Worth USD 69.34 Billion by 2031, at a CAGR of 26.3% – MarketsandMarkets™Yahoo Finance · Nov 4, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
45No pass
Benjamin Graham
37No pass
Philip Fisher
46No pass
Peter Lynch
90Pass
Joel Greenblatt
9No pass
Charlie Munger
38No pass
Terry Smith
30No pass
Questions about Sai Life Sciences
Is Sai Life Sciences a good stock to buy?
A solid business, priced as if everything goes right. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Sai Life Sciences AI analysis
What does Sai Life Sciences do?
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It offers medicinal chemistry, pharmacokinetics, clinical and commercial manufacturing, and process development services. It is in Diagnostics & Research, based in Hyderabad, India.
Is Sai Life Sciences stock halal?
Yes. Sai Life Sciences passes our halal screen: its business is permitted and its debt is 0.7% of its market value, under the 30% limit. How we check
How has Sai Life Sciences stock done over the past year?
Up 119.9% over the past twelve months, to ₹1,927.60. It traded between ₹795.00 and ₹1,927.60, close to its high.
Who are Sai Life Sciences's competitors?
The largest listed companies in the same industry are Thermo Fisher Scientific, Danaher, Waters and WuXi AppTec. The peers table on this page compares their profit, growth and price with Sai Life Sciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.